Lawrence N Kwong

List of Publications by Year
in descending order

65 papers	8,105 citations	147801 31 h-index	110387 64 g-index
68 all docs	68 docs citations	68 times ranked	16826 citing authors

#	Article	IF	Citations
1	The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology, 2022, 75, 297-308.	7.3	32
2	Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nature Biomedical Engineering, 2022, 6, 232-245.	22.5	56
3	Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precision Oncology, 2022, 6, e2100197.	3.0	10
4	IDH1 Inhibition Reawakens the Immune Response against Cholangiocarcinoma. Cancer Discovery, 2022, 12, 604-605.	9.4	0
5	Cost-Efficient Sequence-Based Nonextensible Oligonucleotide in Real-Time PCR and High-Throughput Sequencing. ACS Sensors, 2022, 7, 1165-1174.	7.8	0
6	High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Scientific Reports, 2021, 11, 9043.	3.3	13
7	Cholangiocarcinoma Risk Factors Open the Floodgates for Gut Microbes and Immunosuppressive Myeloid Cells. Cancer Discovery, 2021, 11, 1014-1015.	9.4	6
8	Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene, 2021, 40, 5590-5599.	5.9	33
9	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. Cancer Research, 2021, 81, 5230-5241.	0.9	9
10	Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer. Journal of the American College of Surgeons, 2021, 233, 272-284e13.	0.5	18
11	Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection. Genome Biology, 2021, 22, 227.	8.8	13
12	Calibration-free NGS quantitation of mutations below 0.01% VAF. Nature Communications, 2021, 12, 6123.	12.8	13
13	Same Name, Different Game: EGFR Drives Intrinsic KRASG12C Inhibitor Resistance in Colorectal Cancer. Cancer Discovery, 2020, 10, 1094-1096.	9.4	3
14	Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. JCO Precision Oncology, 2020, 4, 557-569.	3.0	35
15	Insights Into the Origin of Intrahepatic Cholangiocarcinoma From Mouse Models. Hepatology, 2020, 72, 305-314.	7.3	10
16	Generation of An Endogenous FGFR2â€“BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells. International Journal of Molecular Sciences, 2020, 21, 2460.	4.1	3
17	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Scientific Reports, 2020, 10, 22087.	3.3	21
18	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. Clinical Cancer Research, 2019, 25, 6852-6867.	7.0	74

#	Article	IF	Citations
19	Seizure burden pre- and postresection of low-grade gliomas as a predictor of tumor progression in low-grade gliomas. Neuro-Oncology Practice, 2019, 6, 209-217.	1.6	14
20	The path to metastatic mouse models of colorectal cancer. Oncogene, 2018, 37, 2481-2489.	5.9	20
21	In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2â€“CDK4/6 Targeting and mTORâ€“S6 Resistance Mechanisms. Cancer Discovery, 2018, 8, 568-581.	9.4	62
22	A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discovery, 2018, 8, 556-567.	9.4	55
23	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	28.9	2,111
24	Crosstalk between the Notch signaling pathway and long non-coding RNAs. Cancer Letters, 2018, 420, 91-96.	7.2	26
25	Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy. Cancer and Metastasis Reviews, 2018, 37, 45-53.	5.9	30
26	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research, 2018, 24, 4771-4784.	7.0	29
27	Accurate quantification of PGE 2 in the polyposis in rat colon (Pirc) model by surrogate analyte-based UPLCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2018, 148, 42-50.	2.8	8
28	Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precision Oncology, 2018, 2018, 1-19.	3.0	19
29	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-Î² Superfamily. Cell Systems, 2018, 7, 422-437.e7.	6.2	134
30	BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas. Cancer Discovery, 2018, 8, 1064-1065.	9.4	0
31	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature, 2017, 542, 362-366.	27.8	105
32	Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma. Cell Reports, 2017, 19, 1304-1312.	6.4	14
33	Topical Fibronectin Improves Wound Healing of Irradiated Skin. Scientific Reports, 2017, 7, 3876.	3.3	33
34	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports, 2017, 18, 2780-2794.	6.4	416
35	Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes and Development, 2017, 31, 370-382.	5.9	137
36	Loss of the transforming growth factorâ€Î² effector Î²2â€Spectrin promotes genomic instability. Hepatology, 2017, 65, 678-693.	7.3	31

#	Article	IF	Citations
37	miRNAs, Melanoma and Microenvironment: An Intricate Network. International Journal of Molecular Sciences, 2017, 18, 2354.	4.1	43
38	Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget, 2017, 8, 25395-25417.	1.8	64
39	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. Journal of Gastrointestinal Oncology, 2016, 7, 819-827.	1.4	17
40	Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Reports, 2016, 15, 2012-2024.	6.4	46
41	Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Current Treatment Options in Oncology, 2016, 17, 58.	3.0	88
42	MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. Clinical Cancer Research, 2016, 22, 6088-6098.	7.0	43
43	Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Scientific Reports, 2016, 6, 19649.	3.3	15
44	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery, 2016, 6, 827-837.	9.4	785
45	Loss of PTEN Promotes Resistance to T Cellâ€“Mediated Immunotherapy. Cancer Discovery, 2016, 6, 202-216.	9.4	1,158
46	Efficacy of the combination of MEK and CDK4/6 inhibitorsin vitroandin vivoin KRAS mutant colorectal cancer models. Oncotarget, 2016, 7, 39595-39608.	1.8	101
47	Dual Roles of RNF2 in Melanoma Progression. Cancer Discovery, 2015, 5, 1314-1327.	9.4	57
48	Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. Journal of Clinical Investigation, 2015, 125, 1459-1470.	8.2	106
49	Chromosome 10, Frequently Lost in Human Melanoma, Encodes Multiple Tumor-Suppressive Functions. Cancer Research, 2014, 74, 1814-1821.	0.9	15
50	Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Science Signaling, 2014, 7, ra121.	3.6	163
51	Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics. PLoS ONE, 2014, 9, e101286.	2.5	42
52	A Systems Biology Approach to Personalizing Therapeutic Combinations. Cancer Discovery, 2013, 3, 1339-1344.	9.4	4
53	Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma. Clinical Cancer Research, 2013, 19, 5310-5319.	7.0	78
54	Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nature Medicine, 2012, 18, 1503-1510.	30.7	333

#	Article	IF	Citations
55	microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF-Î² Signaling in Glioblastoma. Cancer Discovery, 2012, 2, 736-749.	9.4	99
56	Passenger deletions generate therapeutic vulnerabilities in cancer. Nature, 2012, 488, 337-342.	27.8	294
57	Cerebral White Matter Lesions in Patients with Crohn's Disease. Journal of Neuroimaging, 2012, 22, 38-41.	2.0	29
58	Non-germline genetically engineered mouse models for translational cancer research. Nature Reviews Cancer, 2010, 10, 470-480.	28.4	161
59	Integrative Genome Comparison of Primary and Metastatic Melanomas. PLoS ONE, 2010, 5, e10770.	2.5	166
60	The Brothers RAF. Cell, 2010, 140, 180-182.	28.9	19
61	APC and Its Modifiers in Colon Cancer. Advances in Experimental Medicine and Biology, 2009, 656, 85-106.	1.6	214
62	The Metastasis Problem Gets Stickier. Cancer Cell, 2009, 15, 1-2.	16.8	16
63	A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 4036-4041.	7.1	143
64	Identification of Mom7, a Novel Modifier of ApcMin/+ on Mouse Chromosome 18. Genetics, 2007, 176, 1237-1244.	2.9	43
65	Growth Factors and Oncogenes as Targets in Melanoma: Lost inÂTranslation?. Advances in Dermatology, 2007, 23, 99-129.	2.0	16